ID Week

IDWeek 2024 continues to give encouraging studies. Check out several more from CSL Seqirus and Shionogi.

Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.

Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.

Peter Rabinowitz, MD, MPH, discusses how climate change, including extreme weather and temperature shifts, is reshaping the spread of infectious diseases like dengue, leptospirosis, and Valley fever.

The rise of multidrug-resistant gonorrhea highlights the urgent need for new therapies. Zoliflodacin, a promising oral antibiotic, shows effectiveness in late-stage trials.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending October 29, 2023.

Staying Ahead With Company Updates and Product Innovations. This week's news is from Moderna, CBIC, Helocyte, Pfizer, UVDI, and CloroxPro.

Benjamin Chen, MD, MPH, speaks about how a journal watch in infection prevention keeps professionals updated on research, fosters evidence-based practices, and supports education and quality improvement efforts.

Recent INFORM and EPOCH studies shed light on the significant risk and poor outcomes faced by immunocompromised individuals due to COVID-19, emphasizing the need for tailored prevention strategies.

At IDWeek 2023, a presenter uses HIV as a model to understand the post-acute sequelae of viral infections.

At IDWeek 2023, a session illuminates the importance of accurate diagnosis, current treatments, and what is on the horizon for HSV.

Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA, and SHEA Chair, highlights IDWeek 2023's hybrid format and discusses the critical topic of antimicrobial resistance, emphasizing the role of vaccines in reducing AMR.

The latest news on CLABSIs in the pediatric population is presented at IDWeek 2023.

At IDWeek 2023, a look into managing VAIs in children.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending October 15, 2023.

A study in Maryland from June 2019 to December 2021 analyzed 140 Candida auris cases, revealing that patients often resided in disadvantaged neighborhoods with higher crowding, uninsured rates, and racial diversity. ICT speaks to the lead author.

A phase 3 trial presented at IDWeek 2023 shows that sulbactam-durlobactam (SUL-DUR) reduces mortality and improves outcomes in hospital-acquired Acinetobacter baumannii-calcoaceticus complex infections compared to colistin, offering a promising treatment option.

Dr. Isaac Kohane explores AI's rapid medical evolution and the challenges of accuracy, updating, and education in infectious diseases at IDWeek 2023.

BiomX Develops BX004-A, a Phage Therapy, for Cystic Fibrosis Patients with Pseudomonas Infections. A phase 1b/2a study presents promising results at IDWeek 2023.

Wastewater-based surveillance can accurately monitor influenza A and B and RSV at the population level. This makes it an objective tool to inform public response to common seasonal illnesses.

The investigational mRNA-1647 vaccine discussed at IDWeek 2023 shows great promise in the fight against cytomegalovirus (CMV) infection. Developed using messenger RNA technology, it incorporates essential CMV antigens and has demonstrated safety and effectiveness in clinical evaluations.

This edition of Infection Intel from Infection Control Today covers infection control and prevention company news out of IDWeek, being held in Boston, Massachusetts, from October 11 to 15, 2023.

Most often, the first place a patient enters a hospital is through the emergency department and sometimes by emergency medical services. Where else to better stop Clostridioides difficile from coming into the hospital than at the entrance?

While sequencing-based diagnostics have been used since the 1970s, only recently has the technology been used for infectious diseases.

The respiratory syncytial virus demonstrates effectiveness analyzing severity, age group, and comorbidity in the phase 3 vaccine trial.

Several previously healthy children were admitted for suspected hepatitis and tested positive for human adenovirus. Was there a connection?

Using COVID-19 precautions, and enhanced contact precautions and environmental hygiene, a COVID-19 isolation ward was able to contain an outbreak of CRAB.

Investigators search for increased speed, reliability, and durability in susceptibility testing for C difficile.

The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments.

A recent study demonstrates a tool to help physicians better diagnose the cause of fevers in children.